The company, together with the listed company Erkang pharmaceutical and Shaanxi therapeutic vaccine Engineering Technology Research Center, has established a drug slow control technology platform for polypeptide and protein macromolecular drugs based on PLGA, sodium hyaluronate gel and other excipients, forming an intellectual property protection alliance of excipient product linkage. It was supported by the national "major new drug discovery" (national approval number: 2013ZX09509106).